Abstract

To observe the effect of sodium oligomannate capsules on cognitive dysfunction in Parkinson's disease. 120 patients with cognitive dysfunction were randomly divided into, 60 in treatment and 60 in control group and given sodium oligomannate capsules dose of 5 mg/d, 450 mg/d respectively and compared cognitive function scores (mini-mental state examination, Montreal cognitive assessment). After treatment, serotonin, dopamine, norepinephrine levels and event-related potential are measured. Compared with pre-treatment, the Montreal cognitive assessment and mini-mental state examination scores were significantly different after treatment (both p<0.05), and Montreal cognitive assessment and mini-mental state examination scores were significantly higher after treatment (both p<0.05). Compared to the control group, Montreal cognitive assessment and mini-mental state examination scores before treatment (both p>0.05), and Montreal cognitive assessment and mini-mental state examination scores were significantly increased after treatment (both p<0.01). Before treatment, serum serotonin, dopamine and norepinephrine levels were compared (p>0.05), and serotonin, dopamine and norepinephrine were higher than the control group (p<0.01). The latency period of N2 and P3 was significantly prolonged, and the N2 and P3 incubation periods were significantly reduced, with significant differences (p<0.01). Sodium oligomannate capsules can improve the cognitive function of Parkinson's disease patients by regulating neurotransmitter levels, reducing N2 and P3 latency, improving short and delayed memory and directional force.